Wenfeng Yang1, Yongming Zhang, Zheng Fu, Xiaorong Sun, Dianbin Mu, Jinming Yu. 1. Department of Thoracic Surgery and Shandong Province Medical and Health Key Laboratory of Tumor Surgery, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan 250117 Shandong Province, People's Republic of China.
Abstract
PURPOSE: The aim of this study was to analyse the correlation between (18)F-labelled 3'-deoxy-3'-fluorothymidine ((18)F-FLT) PET/CT proliferation images and tumour angiogenesis as reflected by intratumoral microvessel density (MVD) in non-small-cell lung cancer (NSCLC) to provide a noninvasive method to predict the response to antiangiogenic therapy. METHODS: A total of 68 patients with proven or suspected NSCLC underwent FLT PET/CT scans followed by surgery. PET/CT images were compared with pathology. Tumour proliferation was evaluated in terms of a Ki-67 labelling index (Ki-67 LI). MVD was determined using an anti-CD31 mAb (CD31-MVD), anti-CD34 mAb (CD34-MVD) and an anti-CD105 mAb (CD105-MVD) for each resected tumour. RESULTS: Tumour FLT maximum standardized uptake values (SUVmax) were significantly correlated with the Ki-67 LI and CD105-MVD (r = 0.550 and 0.633, P = 0.000 and 0.000, respectively), but were only marginally correlated with the CD31-MVD and CD34-MVD (r = 0.228 and 0.235, P = 0.062 and 0.054, respectively). The FLT PET false-negative patients had a longer median survival time than the FLT PET true-positive patients (log rank test, P = 0.012). The patients with a lower CD105-MVD had a longer median survival time than those with a higher CD105-MVD (P = 0.046), while patients with a lower CD31-MVD and CD34-MVD did not have a longer median survival time than those with a higher value (P = 0.438 and 0.187, respectively). CONCLUSION: FLT PET/CT imaging correlated with tumour angiogenesis as reflected by CD105-MVD and prognosis, and may be helpful in assessing antiangiogenic therapy of NSCLC.
PURPOSE: The aim of this study was to analyse the correlation between (18)F-labelled 3'-deoxy-3'-fluorothymidine ((18)F-FLT) PET/CT proliferation images and tumour angiogenesis as reflected by intratumoral microvessel density (MVD) in non-small-cell lung cancer (NSCLC) to provide a noninvasive method to predict the response to antiangiogenic therapy. METHODS: A total of 68 patients with proven or suspected NSCLC underwent FLT PET/CT scans followed by surgery. PET/CT images were compared with pathology. Tumour proliferation was evaluated in terms of a Ki-67 labelling index (Ki-67 LI). MVD was determined using an anti-CD31 mAb (CD31-MVD), anti-CD34 mAb (CD34-MVD) and an anti-CD105 mAb (CD105-MVD) for each resected tumour. RESULTS:TumourFLT maximum standardized uptake values (SUVmax) were significantly correlated with the Ki-67 LI and CD105-MVD (r = 0.550 and 0.633, P = 0.000 and 0.000, respectively), but were only marginally correlated with the CD31-MVD and CD34-MVD (r = 0.228 and 0.235, P = 0.062 and 0.054, respectively). The FLT PET false-negative patients had a longer median survival time than the FLT PET true-positive patients (log rank test, P = 0.012). The patients with a lower CD105-MVD had a longer median survival time than those with a higher CD105-MVD (P = 0.046), while patients with a lower CD31-MVD and CD34-MVD did not have a longer median survival time than those with a higher value (P = 0.438 and 0.187, respectively). CONCLUSION:FLT PET/CT imaging correlated with tumour angiogenesis as reflected by CD105-MVD and prognosis, and may be helpful in assessing antiangiogenic therapy of NSCLC.
Authors: Dietmar W Siemann; Michael C Bibby; Graham G Dark; Adam P Dicker; Ferry A L M Eskens; Michael R Horsman; Dieter Marmé; Patricia M Lorusso Journal: Clin Cancer Res Date: 2005-01-15 Impact factor: 12.531
Authors: A Giatromanolaki; M I Koukourakis; D Theodossiou; K Barbatis; K O'Byrne; A L Harris; K C Gatter Journal: Clin Cancer Res Date: 1997-12 Impact factor: 12.531
Authors: Andreas K Buck; Holger Schirrmeister; Martin Hetzel; Mareike Von Der Heide; Gisela Halter; Gerhard Glatting; Torsten Mattfeldt; Florian Liewald; Sven N Reske; Bernd Neumaier Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: B Martin; M Paesmans; C Mascaux; T Berghmans; P Lothaire; A-P Meert; J-J Lafitte; J-P Sculier Journal: Br J Cancer Date: 2004-12-13 Impact factor: 7.640
Authors: Matthew Scarpelli; Justine Yang Bruce; Lakeesha Carmichael; Jens Eickhoff; Jill Kolesar; Scott Perlman; Robert Jeraj; Glenn Liu Journal: Cancer Chemother Pharmacol Date: 2016-11-05 Impact factor: 3.333
Authors: Stephen A Deppen; Jeffrey D Blume; Clark D Kensinger; Ashley M Morgan; Melinda C Aldrich; Pierre P Massion; Ronald C Walker; Melissa L McPheeters; Joe B Putnam; Eric L Grogan Journal: JAMA Date: 2014-09-24 Impact factor: 56.272